Expanding Adjuvant Therapy in RCC
The group discusses how the addition of belzutifan to adjuvant pembrolizumab may represent an important next step in high-risk RCC, particularly given the persi...
Watch NowFuture Directions in RCC: Triplets, Biomarkers, and Neoadjuvant Strategies
Drs. Barata, McGregor, Shah, and Serzan discuss how new adjuvant and metastatic RCC data are opening the door to more personalized and potentially more effectiv...
Read More
Latest Videos
Sequencing Lenvatinib-Based Therapy in Refractory RCC
Drs. Peter Barata, Brad McGregor, Neil Shah, and Michael Serzan discuss how emerging second-line options like lenvatinib plus belzutifan may expand treatment ch...
Watch Now
Belzutifan Combinations and Second-Line Strategy in RCC
The panel outlines a clear shift in second-line renal cell carcinoma management, emphasizing that immunotherapy should not be continued after progression and th...
Watch Now
Frontline vs Second-Line RCC Strategy: Why Getting the First Choice Right Matters
Drs. Pedro Barata, Brad McGregor, Neil Shah, and Michael Serzan emphasize that in advanced RCC, treatment decisions should prioritize the best option in the mom...
Watch Now
Frontline RCC Treatment: Matching the Right Regimen to the Right Patient
Drs. Pedro Barata, Brad McGregor, Neil Shah, and Michael Serzan discuss how frontline treatment selection in advanced clear cell RCC depends on balancing long-t...
Watch Now